Artivion
AORT

$25.11

1.95%

Market Cap: $1.05B

About: Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others.

Employees: 1,500

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

258% more call options, than puts

Call options by funds: $623K | Put options by funds: $174K

68% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 19

15% more capital invested

Capital invested by funds: $793M [Q1] → $912M (+$120M) [Q2]

9% more funds holding

Funds holding: 150 [Q1] → 163 (+13) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

5.67% less ownership

Funds ownership: 90.88% [Q1] → 85.21% (-5.67%) [Q2]

16% less repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 56

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$28

12%

upside

Avg. target

$30

17%

upside

High target

$30

19%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

Needham Mike Matson 64% 1-year accuracy 72 / 113 met price target	19%upside $30	Buy Reiterated	9 Aug 2024
Oppenheimer Suraj Kalia 53% 1-year accuracy 9 / 17 met price target	19%upside $30	Outperform Maintained	9 Aug 2024
Stifel Rick Wise 68% 1-year accuracy 19 / 28 met price target	12%upside $28	Buy Maintained	9 Aug 2024
Lake Street Frank Takkinen 53% 1-year accuracy 10 / 19 met price target	19%upside $30	Buy Maintained	2 Jul 2024

See Analyst Rankings

Financial journalist opinion

Artivion, Inc. (AORT) Q2 2024 Earnings Call Transcript

Artivion, Inc. (NYSE:AORT ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Eileen Martin - Investor Relations Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Suraj Kalia - Oppenheimer John McAulay - Stifel Jeffrey Cohen - Ladenburg Thalmann Operator Greetings. And welcome to Artivion's Second Quarter 2024 Financial Conference Call.

Artivion, Inc. (AORT) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Artivion (AORT) Surpasses Q2 Earnings and Revenue Estimates

Artivion (AORT) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.06 per share a year ago.

Artivion (AORT) Surpasses Q2 Earnings and Revenue Estimates

Artivion Reports Second Quarter 2024 Financial Results

Second Quarter Highlights: Achieved revenue of $98.0 million in the second quarter of 2024 versus $89.3 million in the second quarter of 2023, an increase of 10% on both a GAAP and constant currency basis Net loss was ($2.1) million or ($0.05) per fully diluted share and non-GAAP net income was $2.9 million or $0.07 per fully diluted share in the second quarter of 2024 Adjusted EBITDA increased 35% to $18.6 million in the second quarter of 2024 compared to $13.8 million in the second quarter of 2023 Raised FY24 revenue guidance to 10% to 12% year-over-year growth on a constant currency basis, an increase of 0.5% at the midpoint Raised FY24 adjusted EBITDA guidance to 28% to 34% year-over-year growth, an increase of 1% at the midpoint ATLANTA , Aug. 8, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2024. "In the second quarter, we continued to make substantial progress on our strategic growth initiatives to drive sustained and profitable growth, and we further solidified our position as the leader in the aortic disease space.

Artivion Reports Second Quarter 2024 Financial Results

Artivion to Participate in Upcoming Investor Conferences

ATLANTA , Aug. 5, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion's management team will present at the upcoming Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, 2024 at the InterContinental Boston Hotel.

Artivion to Participate in Upcoming Investor Conferences

Investors Business Daily

7 Best Stocks For Magnificent Earnings Growth Next Year. See Who's New.

None of our picks is Nvidia or Apple or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.

7 Best Stocks For Magnificent Earnings Growth Next Year. See Who's New.

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results

ATLANTA , July 25, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2024 financial results will be released on Thursday, August 8, 2024 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results

3 Earnings All-Stars With More Room to Run

Earnings are essential to determining which stocks will outperform. Unsurprisingly, earnings outperformers also see strong price appreciation.

3 Earnings All-Stars With More Room to Run

Artivion Amends Agreements with Endospan

Provides Endospan with $25 million of Additional Debt Funding to Obtain FDA Approval for NEXUS Upfront Payment Associated with Purchase Option Reduced to $135 million, inclusive of loan off-set, and $100 million earnout minimum eliminated ATLANTA , July 1, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced it has amended its credit facility and option purchase agreements with Endospan Ltd. ("Endospan"), an Israeli-based, privately-held developer of the NEXUS® Stent Graft System ("NEXUS").

Artivion Amends Agreements with Endospan

Data-Driven Growth Fuels More Upside For Overlooked Artivion

Artivion, Inc. has continued to log double-digit revenue growth with contributions from diverse assets including its stent grafts, heart valves, and cryopreserved tissue grafts. Positive post-approval trial data for the On-X aortic valve and a successful PERSEVERE IDE study for AMDS hybrid prosthesis can drive additional revenue growth. A strong pipeline, including NEXUS and ARCEVO stent graft systems, can support a longer runway of continued revenue growth.

Data-Driven Growth Fuels More Upside For Overlooked Artivion

Zacks Investment Research

Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?

Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?

See News Rankings